Reports on the phase II trial of 13-cis-retinoic acid plus interferon alpha in patients with locally advanced or metastatic non-small-cell lung cancer. Daily dosage of 13-cis-retinoic acid; Toxic effects recorded by patients; Inactivity of the combined treatment.